Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nervgen Pharma Corp (NGEN.VN)

Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 466,562
  • Shares Outstanding, K 79,213
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,006 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings $-0.06 on 11/24/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.250 +5.33%
on 02/06/26
6.050 -8.60%
on 02/23/26
+0.270 (+5.13%)
since 02/05/26
3-Month
5.110 +8.22%
on 02/02/26
8.490 -34.86%
on 01/08/26
-0.270 (-4.66%)
since 12/05/25
52-Week
2.570 +115.18%
on 06/02/25
8.490 -34.86%
on 01/08/26
+2.750 (+98.92%)
since 03/05/25

Most Recent Stories

More News
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 4.04 (-5.39%)
NGEN.VN : 5.530 (-6.11%)
Upcoming Meeting Dates - February 23, 2026

Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies...

ELD.TO : 55.27 (-2.71%)
SCD.VN : 0.190 (-2.56%)
STE.VN : 0.590 (-0.84%)
WPRT.TO : 2.79 (-2.11%)
GMTN.VN : 1.830 (-4.94%)
WGO.VN : 1.970 (-4.83%)
ISGI.VN : 0.010 (unch)
SLF.TO : 89.54 (+0.20%)
VGZ.TO : 3.38 (-3.70%)
ARX.TO : 25.91 (+1.17%)
WPM.TO : 202.07 (-3.78%)
CRI.VN : 0.140 (+7.69%)
NervGen Pharma to Participate at Upcoming Investor Conferences

VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 4.04 (-5.39%)
NGEN.VN : 5.530 (-6.11%)
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 4.04 (-5.39%)
NGEN.VN : 5.530 (-6.11%)
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence,...

NGEN : 4.04 (-5.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.530 (-6.11%)
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 4.04 (-5.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.530 (-6.11%)
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 4.04 (-5.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.530 (-6.11%)
NervGen Pharma Begins Trading on Nasdaq Today

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 4.04 (-5.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.530 (-6.11%)
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.530 (-6.11%)
NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.530 (-6.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial...

See More

Key Turning Points

3rd Resistance Point 6.170
2nd Resistance Point 6.010
1st Resistance Point 5.770
Last Price 5.530
1st Support Level 5.370
2nd Support Level 5.210
3rd Support Level 4.970

See More

52-Week High 8.490
Fibonacci 61.8% 6.229
Fibonacci 50% 5.530
Last Price 5.530
Fibonacci 38.2% 4.831
52-Week Low 2.570

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar